ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia

Dopamine (DA) neurons degenerate in Parkinson's disease and dopamine neurotransmission may be affected in psychotic states seen in schizophrenia. Understanding the regulation of enzymes involved in DA metabolism may therefore lead to new treatment strategies for these severe conditions. We investigated mRNA expression of the cytosolic aldehyde dehydrogenase (ALDH1), presumably involved in DA degradation, by in situ hybridization in DA neurons of human postmortem material. Parallel labeling for GAPDH, neuron-specific enolase, tyrosine hydroxylase, dopamine transporter, and dopamine beta-hydroxylase was used to ensure suitability of tissue specimen and to identify all dopamine neurons. ALDH1 was found to be expressed highly and specifically in DA cells of both substantia nigra (SN) and the ventral tegmental area (VTA) of controls. A marked reduction of ALDH1 expression was seen in surviving neurons of SN pars compacta but not of those in the VTA in Parkinson's disease. In patients suffering from schizophrenia we found ALDH1 expression at normal levels in DA cells of SN but at significantly reduced levels in those of the VTA. We conclude that ALDH1 is strongly and specifically expressed in human mesencephalic dopamine neurons and that low levels of ALDH1 expression correlate with DA neuron dysfunction in the two investigated human conditions.

[1]  R. Pontcharraud,et al.  Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes , 1998, Neurochemistry International.

[2]  P. Dostert,et al.  Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases , 2005, Journal of Neural Transmission.

[3]  G. Sedvall,et al.  NURR1 mutations in cases of schizophrenia and manic-depressive disorder. , 2000, American journal of medical genetics.

[4]  M. Anvret,et al.  Alcohol dehydrogenase alleles in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[5]  M. O’Donovan,et al.  Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA levels in rat brain following antipsychotic treatment , 2005, Psychopharmacology.

[6]  J. Holden,et al.  Effects of Catechol-O-methyltransferase Inhibition on the Rates of Uptake and Reversibility of 6-Fluoro-l-Dopa Trapping in MPTP-induced Parkinsonism in Monkeys , 1997, Neuropharmacology.

[7]  R. Little,et al.  Partial Purification and Properties of Human Brain Aldehyde Dehydrogenases , 1985, Journal of neurochemistry.

[8]  U. Dräger,et al.  Retinoic acid synthesizing enzymes in the embryonic and adult vertebrate. , 1995, Advances in experimental medicine and biology.

[9]  G. Jonsson,et al.  FLUORESCENCE METHODS FOR THE HISTOCHEMICAL DEMONSTRATION OF MONOAMINES: 4. HISTOCHEMICAL DIFFERENTIATION BETWEEN DOPAMINE AND NORADRENALINE IN MODELS , 1965, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  C. Barraclough,et al.  Effects of reserpine on tyrosine hydroxylase mRNA levels in locus coeruleus and medullary A1 and A2 neurons analyzed by in situ hybridization histochemistry and quantitative image analysis methods. , 1992, Brain research. Molecular brain research.

[11]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B J Hoffer,et al.  Dopamine neuron agenesis in Nurr1-deficient mice. , 1997, Science.

[13]  J. Parkinson An Essay on the Shaking Palsy , 2002 .

[14]  R. Satran,et al.  Disulfiram (Antabuse) psychosis. , 1967, The American journal of psychiatry.

[15]  Y. Mizuno,et al.  Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain , 1990, Neurochemical Research.

[16]  U. Dräger,et al.  High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A Carlsson,et al.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.

[18]  D. Petersen,et al.  Metabolism of malondialdehyde by rat liver aldehyde dehydrogenase. , 1983, Toxicology and applied pharmacology.

[19]  L. Olson,et al.  Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. , 1996, Molecular endocrinology.

[20]  W. Burke,et al.  Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. , 2001, Free radical biology & medicine.

[21]  W. Burke,et al.  3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. , 2001, Brain research. Molecular brain research.

[22]  T. Nagatsu,et al.  An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.

[23]  E. Mendez-Alvarez,et al.  Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro-β-carboline by cigarette smoke , 2001, Neuroscience Letters.

[24]  Steven A. Johnson,et al.  Tyrosine Hydroxylase mRNA Concentration in Midbrain Dopaminergic Neurons Is Differentially Regulated by Reserpine , 1990, Journal of neurochemistry.

[25]  H. Braak,et al.  Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[26]  G. Duester Genetic dissection of retinoid dehydrogenases. , 2001, Chemico-biological interactions.

[27]  Murthy Kk Psychosis during disulfiram therapy for alcoholism. , 1997 .

[28]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[29]  T. Montine,et al.  4‐Hydroxy‐2‐Nonenal Pyrrole Adducts in Human Neurodegenerative Disease , 1997, Journal of neuropathology and experimental neurology.

[30]  L. Olson,et al.  Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. , 1999, Experimental cell research.

[31]  Kurt Jellinger,et al.  Amygdala pathology in Parkinson's disease , 2004, Acta Neuropathologica.

[32]  O. Hornykiewicz [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease]. , 1963, Wiener klinische Wochenschrift.

[33]  D. Calne Developments in the pharmacology and therapeutics of parkinsonism , 1977, Annals of neurology.

[34]  T. Niwa,et al.  Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.

[35]  A. Kingsbury,et al.  The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: An in situ hybridization study , 1999, Movement disorders : official journal of the Movement Disorder Society.

[36]  T. Nagatsu,et al.  Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. , 1993, Advances in neurology.

[37]  T. Hökfelt,et al.  Sensitive mRNA detection using unfixed tissue: combined radioactive and non-radioactive in situ hybridization histochemistry , 1992, Histochemistry.

[38]  S. Lightman,et al.  Neuropeptide Y and tyrosine hydroxylase mRNA levels in the locus coeruleus show similar increases after reserpine treatment , 1991, Neuropeptides.

[39]  A. Pictet,et al.  Über die Bildung von Isochinolin‐derivaten durch Einwirkung von Methylal auf Phenyl‐äthylamin, Phenyl‐alanin und Tyrosin , 1911 .

[40]  M. Selley (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. , 1998, Free radical biology & medicine.

[41]  H Bratzke,et al.  Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. , 1998, Progress in brain research.

[42]  J. Scher Psychotic reaction to disulfiram. , 1967, JAMA.

[43]  S. Paul,et al.  Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration , 1990, Cellular and Molecular Neurobiology.

[44]  A. Yoshida,et al.  Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. , 1992, Enzyme.

[45]  H. Esterbauer,et al.  Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. , 1985, The Biochemical journal.

[46]  Eriksson Cj Regulation of acetaldehyde metabolism during ethanol oxidation in perfused rat liver. , 1977 .

[47]  M. Collins Neuroamine condensations in human subjects. , 1980, Advances in experimental medicine and biology.

[48]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[49]  L. Olson,et al.  Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. , 1996, Brain research. Molecular brain research.

[50]  A. Yoshida,et al.  Structural mutation in a major human aldehyde dehydrogenase gene results in loss of enzyme activity. , 1982, American journal of human genetics.

[51]  A. Yoshida,et al.  Genomic structure of the human cytosolic aldehyde dehydrogenase gene. , 1989, Genomics.